Cantor Fitzgerald Reiterates Overweight on Zevra Therapeutics
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Zevra Therapeutics (NASDAQ:ZVRA).
August 05, 2024 | 1:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Zevra Therapeutics, indicating a positive outlook for the stock.
The reiteration of an Overweight rating by a reputable analyst suggests confidence in the company's future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100